

## Disclosures

### Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Alleviant Medical	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Axon Therapeutics	Research/Research Grants ‡ <i>REBALANCE-HF (site PI)</i>	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Corvia	Research/Research Grants ‡ <i>REDUCE LAP-HF (site PI), REDUCE LAP-HF 2 (site PI), RESPONDER-HF (site PI)</i>	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Intellia Therapeutics	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Other</a>
Novartis	Research/Research Grants	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (7)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
AHRQ	Research/Research Grants	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
American Heart Association	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Other</a>
NIH/NHLBI	Research/Research Grants ‡ <i>SPIRRIT-HFpEF (site PI)</i>	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
NIH/NHLBI	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
NIH/NIA	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Veterans Health Administration	Research/Research Grants ‡ <i>Cooperative Study #2025 (Study Chair)</i>	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Veterans Health Administration	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Prevention</a>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation

| Signed on 10/15/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement

| Signed on 10/15/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo

| Signed on 10/15/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.